Velo3D, Inc.
VELO Nasdaq Special Industry Machinery, Nec Financials FY2020βFY2025
What Velo3D, Inc. does
No business description yet.
- Legal name
- Velo3D, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 31, 2026
- Accession Β· CIK
- 0001193125-26-134997
0001825079
Revenue and margins
Velo3D, Inc. had $46.0M of revenue in fiscal 2025, up 12.1% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$30.0M in fiscal 2025, β65.3% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Velo3D, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 1,845.8%.
Balance sheet
Cash, debt and the ratios that show how comfortably Velo3D, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $223M | $80.2M | $31.1M | $1.2M | $39.0M |
| Debt incl. finance leases | β | $8.4M | $44.3M | $11.6M | $31.3M |
| Debt / equity | β | 0.1x | 0.6x | 0.3x | 0.8x |
| Interest coverage | β21.1x | β285.8x | β13.7x | β4.9x | β12.6x |
| Current ratio | 5.7x | 3.7x | 2.3x | 1.5x | 2.4x |
| Quick ratio | 5.3x | 2.2x | 1.1x | 0.2x | 1.6x |
| Total assets | $303M | $223M | $154M | $89.2M | $105M |
| Total liabilities | $192M | $84.3M | $85.5M | $49.5M | $67.2M |
| Shareholders' equity | $110M | $139M | $68.3M | $39.7M | $38.2M |
| Net debt (β = net cash) | β | β$71.8M | $13.2M | $10.4M | β$7.7M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 8 | 3 / 8 | 3 / 9 | 5 / 9 | 3 / 9 |
| Accruals ratio | 14.2% | β30.2% | 50.2% | β15.7% | β30.5% | β45.3% |
| Altman Z'' | β20.17 | 1.64 | β1.03 | β9.81 | β19.25 | β15.44 |
6 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $19.0M | $27.4M | $78.7M | $77.4M | $41.0M | $46.0M |
| Gross profit | $6.4M | $5.0M | $0.8M | β$26.3M | β$2.1M | β$7.4M |
| Research and development | $14.2M | $27.0M | $46.3M | $42.0M | $15.5M | $10.7M |
| Operating income | β$21.2M | β$57.8M | β$106M | β$133M | β$78.8M | β$54.9M |
| Interest expense | $0.6M | $2.7M | $0.4M | $9.7M | $16.0M | $4.4M |
| Pretax income | β$21.8M | β$107M | $8.0M | β$135M | β$69.8M | β$71.2M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | β$0.0M | $0.1M |
| Net income | β$21.8M | β$107M | $8.0M | β$135M | β$69.7M | β$71.4M |
| Net income to common | β$8.8M | β$107M | β | β | β | β |
| Diluted EPS | β$0.56 | β$1.82 | $0.04 | β$23.97 | β$82.32 | β$4.33 |
| Diluted shares | 0.02B | 0.06B | 0.20B | 0.01B | 0.00B | 0.02B |
| Cash flow | ||||||
| Cash from operations | β$26.4M | β$56.4M | β$124M | β$106M | β$32.7M | β$27.3M |
| Capital expenditure | $0.4M | $9.6M | $13.8M | $1.0M | $0.0M | $2.7M |
| Free cash flow | β$26.8M | β$66.0M | β$138M | β$107M | β$32.7M | β$30.0M |
| Depreciation and amortization | $1.2M | $3.0M | $5.3M | $9.3M | $4.8M | $3.4M |
| Stock-based compensation | $1.5M | $4.4M | $20.1M | $24.9M | $11.8M | $9.5M |
| Balance sheet | ||||||
| Cash and short-term investments | $15.5M | $223M | $80.2M | $31.1M | $1.2M | $39.0M |
| Total debt | β | β | $8.4M | $44.0M | $11.3M | $31.0M |
| Finance lease liabilities | $0.0M | $0.1M | $0.0M | $0.3M | $0.3M | $0.3M |
| Current assets | $27.9M | $268M | $172M | $113M | $57.7M | $80.1M |
| Current liabilities | $12.1M | $46.7M | $46.1M | $48.7M | $38.0M | $33.8M |
| Inventory | $7.3M | $22.5M | $71.2M | $60.8M | $50.0M | $27.1M |
| Property and equipment, net | $1.0M | $10.0M | $19.8M | $16.3M | $14.3M | $13.1M |
| Total assets | $32.7M | $303M | $223M | $154M | $89.2M | $105M |
| Total liabilities | $16.8M | $192M | $84.3M | $85.5M | $49.5M | $67.2M |
| Shareholders' equity | β$108M | $110M | $139M | $68.3M | $39.7M | $38.2M |
| Margins | ||||||
| Gross margin | 33.6% | 18.1% | 1.1% | β33.9% | β5.1% | β16.1% |
| Operating margin | β111.8% | β210.5% | β135.1% | β172.1% | β192.2% | β119.5% |
| EBITDA margin | β105.2% | β199.5% | β128.4% | β160.0% | β180.5% | β112.1% |
| Net margin | β114.9% | β390.3% | 10.1% | β174.5% | β170.1% | β155.2% |
| FCF margin | β141.5% | β240.6% | β175.1% | β137.8% | β79.7% | β65.3% |
| Returns | ||||||
| Return on capital | β | β | β158.8% | β129.6% | β125.0% | β143.9% |
| Return on capital employed | β103.1% | β22.6% | β60.1% | β126.8% | β154.0% | β76.8% |
| Return on equity | β | β8,256.8% | 6.4% | β130.5% | β129.2% | β183.4% |
| Return on assets | β66.7% | β63.9% | 3.0% | β71.7% | β57.4% | β73.4% |
| Return on tangible equity | β | β97.0% | 5.7% | β197.7% | β175.8% | β187.0% |
| Growth | ||||||
| Revenue growth | β | 44.6% | 186.8% | β1.6% | β47.1% | 12.1% |
| Net income growth | β | β | β | β1,795.8% | β | β |
| EPS growth | β | β | β | β60,025.0% | β | β |
| Share count change | β | 275.5% | 244.5% | β97.2% | β85.0% | 1,845.8% |
| Financial health | ||||||
| Debt / equity | β | β | 0.1x | 0.6x | 0.3x | 0.8x |
| Interest coverage | β33.2x | β21.1x | β285.8x | β13.7x | β4.9x | β12.6x |
| Current ratio | 2.3x | 5.7x | 3.7x | 2.3x | 1.5x | 2.4x |
| Quick ratio | 1.7x | 5.3x | 2.2x | 1.1x | 0.2x | 1.6x |
| Capital allocation | ||||||
| Capex / revenue | 2.1% | 35.1% | 17.6% | 1.4% | 0.0% | 5.9% |
| Stock comp / revenue | 7.7% | 15.9% | 25.6% | 32.2% | 28.8% | 20.7% |
| Quality scores | ||||||
| Piotroski F-score | β | 3.0 | 3.0 | 3.0 | 5.0 | 3.0 |
| Altman Z'' | β20.2 | 1.6 | β1.0 | β9.8 | β19.2 | β15.4 |
| Accruals ratio | 14.2% | β30.2% | 50.2% | β15.7% | β30.5% | β45.3% |
Source: SEC EDGAR XBRL filings (CIK 0001825079). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.